• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,797.61 910.70
( 1.18%)
Global Indices
Nasdaq
49,166.29 -22.51
(-0.05%)
Dow Jones
7,159.57 -35.34
(-0.49%)
Hang Seng
59,839.06 -698.30
(-1.15%)
Nikkei 225
10,332.91 11.82
(0.11%)
Forex
USD-INR
94.18 0.27
(0.28%)
EUR-INR
110.46 0.44
(0.40%)
GBP-INR
127.53 0.53
(0.42%)
JPY-INR
0.59 0.00
(0.34%)

EQUITY - MARKET SCREENER

Piramal Pharma Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
543635
INE0DK501011
58.2770662
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
PPLPHARMA
29.6
21839.55
EPS(TTM)
Face Value()
Div & Yield %
5.55
10
0.08
 

urja global ltd
Bombay Dyeing slumps on reporting dismal Q3 performance
Feb 12,2026
Revenue from operations declined 21.9% year-on-year to Rs 324.02 crore in the quarter ended 31 December 2025.

The company reported a loss before tax of Rs 12.64 crore in Q3 FY26, as against a profit before tax of Rs 93.91 crore in Q3 FY25.

Total expenses declined 11.17% year-on-year to Rs 362.43 crore during the quarter. The cost of raw materials fell 26.78% to Rs 204.10 crore, while employee benefit expenses surged 451.07% YoY to Rs 48.99 crore.

Meanwhile, the company announced the resignation of Khiroda Jena, chief financial officer & chief risk officer (CFO & CRO) and key managerial personnel of the company, effective from the closure of business hours on 13 February, 2026.

Bombay Dyeing & Manufacturing Company is currently engaged in the business of real estate development, polyester staple fiber, and retail (textiles).